Chinese Traditional and Herbal Drugs
|
2025, 56(14): 5049-5060
Astragaloside Ⅳ inhibits renal fibrosis induced by renal ischemia-reperfusion injury in mice through modulation of TPL2-CTGF signaling pathway
Full
Affiliations
About Author:
国家自然科学基金青年项目 (82304809)
doi: 10.7501/j.issn.0253-2670.2025.14.011
Outline
Objective To investigate astragaloside Ⅳ (AS-Ⅳ) alleviates renal fibrosis following ischemia-reperfusion injury (IRI) by modulating tumor progression locus 2 (TPL2)-connective tissue growth factor (CTGF) signaling pathway and elucidate its intervention in preventing the progression from acute kidney injury (AKI) to chronic kidney disease (CKD).Methods A IRI mice model was established via unilateral renal artery clamping. Sham group, model group, AS-Ⅳ low- and high-dose (40, 80 mg/kg) groups were set up. Samples were collected on postoperative days 1 and 28 to investigate the effect of AS-Ⅳ on acute renal ischemia-reperfusion injury and fibrosis in mice after renal ischemia-reperfusion injury. Renal function was assessed by measuring serum creatinine (Scr) and blood urea nitrogen (BUN). Renal histopathological injury and fibrosis were evaluated using hematoxylin-eosin (HE) staining, periodic acid-schiff (PAS) staining, Masson staining and Sirius red staining. An in vitro injury model was established using human kidney-2 (HK-2) cells induced by transforming growth factor-β1 (TGF-β1), and molecular mechanisms were explored by transfecting HK-2 cells with small interfering RNA (siRNA) targeting TPL2. Western blotting was used to detect the protein expression levels of fibrosis markers including α-smooth muscle actin (α-SMA), collagen I (COL1), TGF-β1, as well as TPL2, CTGF, and the downstream inflammatory factor tumor necrosis factor-α (TNF-α) in kidney of mice and HK-2 cells.Results In the acute phase of renal injury post-IRI, AS-Ⅳ significantly reduced Scr and BUN levels (P < 0.001), alleviated tubular dilation and brush border loss. During the fibrotic progression phase, AS-Ⅳ persistently suppressed the elevation of Scr and BUN (P < 0.05, 0.01, 0.001), while reduced collagen fiber deposition in the renal interstitium (P < 0.001). Western blotting results showed that AS-Ⅳ dose-dependently down-regulated the protein expressions of TPL2 and its downstream effector CTGF (P < 0.001), and significantly inhibited the expression levels of renal interstitial fibrosis related proteins (P < 0.05, 0.01, 0.001). In vitro experiments results showed that AS-Ⅳ markedly inhibited the TGF-β1-induced overexpressions of TPL2, CTGF, α-SMA and TNF-α (P < 0.01, 0.001). After transfection with si-TPL2 and continued treatment with AS-Ⅳ, there was no significant difference in the expression levels of TPL2, CTGF, α-SMA and TNF-α compared to AS-Ⅳ treated group alone.Conclusion AS-Ⅳ attenuates post-IRI renal inflammation and fibrosis by inhibiting the TPL2-CTGF pathway, thereby preventing AKI-to-CKD progression, which provide a potential therapeutic strategy for the clinical management of ischemic kidney injury.
astragaloside Ⅳ
/
TPL2
/
CTGF
/
renal ischemia-reperfusion
/
renal fibrosis
徐静鸽, 武佳慧, 李星怡, 张之钰, 董湲睿, 王丹, 吴昱铮, 王涛, 陈倩.
黄芪甲苷通过调控TPL2-CTGF信号通路抑制小鼠肾缺血再灌注损伤诱导的肾纤维化.
中草药,
2025
, 56
(14)
: 5049
-5060
.
DOI: 10.7501/j.issn.0253-2670.2025.14.011
XU Jingge, WU Jiahui, LI Xingyi, ZHANG Zhiyu, DONG Yuanrui, WANG Dan, WU Yuzheng, WANG Tao, CHEN Qian.
Astragaloside Ⅳ inhibits renal fibrosis induced by renal ischemia-reperfusion injury in mice through modulation of TPL2-CTGF signaling pathway[J].
Chinese Traditional and Herbal Drugs,
2025
, 56
(14)
: 5049
-5060
.
DOI: 10.7501/j.issn.0253-2670.2025.14.011
Year 2025 volume 56 Issue 14
50
0
Cite this Article
BibTeX
Article Info
doi: 10.7501/j.issn.0253-2670.2025.14.011
- Receive Date:2025-04-07
- Online Date:2026-11-12